Captrust Financial Advisors Beam Therapeutics Inc. Transaction History

Captrust Financial Advisors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$29.86 - $62.36 $11,944 - $24,944	-400 Reduced 26.2%	1,127 $44,000
Q2 2022 Aug 16, 2022	SELL	$29.86 - $62.36 $9,495 - $19,830	-318 Reduced 17.24%	1,527 $59,000
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $22,835 - $34,918	425 Added 29.93%	1,845 $106,000
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $187,327 - $272,811	-2,754 Reduced 65.98%	1,420 $113,000
Q3 2021 Nov 16, 2021	BUY	$84.37 - $133.6 $70,195 - $111,155	832 Added 24.9%	4,174 $363,000
Q2 2021 Aug 16, 2021	SELL	$64.12 - $128.71 $45,781 - $91,898	-714 Reduced 17.6%	3,342 $430,000
Q1 2021 May 17, 2021	BUY	$71.28 - $120.75 $219,257 - $371,427	3,076 Added 313.88%	4,056 $325,000
Q4 2020 Feb 16, 2021	BUY	$22.24 - $95.63 $6,227 - $26,776	280 Added 40.0%	980 $80,000
Q2 2020 Aug 14, 2020	BUY	$15.26 - $28.66 $10,682 - $20,062	700 New	700 $20,000

233

75.1M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.83B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.